Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

Fig. 3

Kaplan–Meier curves for PFS and OS of BPI-9016M treated patients. A: Kaplan–Meier curve of PFS for all patients (N = 38). B: Kaplan–Meier curve of PFS for all four dose cohorts (300 mg QD, 450 mg QD, 600 mg QD and 400 mg BID). C: Kaplan–Meier curve of OS for all patients (N = 38). D: Kaplan–Meier curve of OS for all four dose cohorts (300 mg QD, 450 mg QD, 600 mg QD and 400 mg BID)

 PFS progression-free survival, OS overall survival, QD quaque die, BID bis in die, CI confidence interval, NE not evaluable

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us